Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association
Oral Presentation Details Dose Optimization of Pre-Clinical Otelixizumab Surrogate
NEW ORLEANS, June 8 /PRNewswire/ -- Tolerx, Inc., a biopharmaceutical company engaged in the discovery and development of novel therapies for immune-mediated diseases, today presented results from a pre-clinica...
SCAI Statement on the BARI 2D Trial (Bypass Angioplasty Revascularization Investigation With Diabetes Trial) Presented at the American Diabetes Association (ADA) Annual Scientific Sessions and Published in The New England Journal of Medicine
WASHINGTON, June 7 /PRNewswire/ -- BARI-2D is a useful and focused trial that builds on the body of scientific knowledge physicians use to provide the best possible care for diabetic patients with chronic stable angina and to evaluate their treatment options. The Society for Cardiovascular Angiog...
Society of Gynecologic Oncologists 40th Annual Meeting on Women's Cancer to Include Sessions on Robotics Surgery
How is this New Surgery Technique Impacting the Treatment of Women's Cancers?
CHICAGO, Jan. 29 /PRNewswire-USNewswire/ -- Robotic-assisted surgery has become one of the fastest growing technological advances in the field of Gynecologic Oncology in the past few years. This minimally-invasive s...
Portola Announces Data Presentations Relevant to Its Lead Phase II Antithrombotic Compounds at American Heart Association Scientific Sessions 2008
SOUTH SAN FRANCISCO, Calif., Nov. 6 /PRNewswire/ -- Portola
Pharmaceuticals, a biopharmaceutical company developing innovative drugs
that provide significant advances in cardiovascular and inflammatory
diseases, and cancer, today announced that data relevant to betrixaban, the
company's novel ...
VIA Pharmaceuticals to Present at American Heart Association Scientific Sessions 2008
Topline Data from Phase 2 CEA and ACS Clinical Trials to be Released Concurrent with AHA Presentation
SAN FRANCISCO, Sept. 15 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals,
Inc. (Nasdaq: VIAP ), a biotechnology company focused on the development of
compounds for the treat...
Data Presented at the American Heart Association Scientific Sessions 2007 Demonstrated Increased HDL with ACTOS(R) (pioglitazone HCl) Slowed the Progression of Carotid Intima-Media Thickness in Patients with Type 2 Diabetes
ORLANDO, Fla., Nov. 6 /PRNewswire/ -- What and When Additional results from the clinical trial, CHICAGO (Carotid
intima-media tHICkness in Atherosclerosis using pioGlitazOne), will be
presented as an oral session at the American Heart Association Scientific
Sessions 2007 being held November ...
OrbusNeich's Genous(TM) Bio-Engineered R Stent(TM) is Subject of Sessions on Innovation at TCT 2007
Latest Randomized Clinical Trial Results of First Pro-Healing Stent Also Featured at Annual Symposium
HONG KONG, Oct. 18 /PRNewswire/ -- OrbusNeich's Genous(TM)
Bio-engineered R stent(TM) is the subject of several sessions
innovation in interventional cardiology stra...
Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity at ADA Scientific Sessions
NEW ORLEANS and CARLSBAD, Calif., June 9 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) announced today that Isis' antisense drugs were highlighted with eight presentations (including three oral talks and two late-breaking posters) during the American Diabetes Association's...
Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Association's 69th Scientific Sessions
- Late-Breaking Abstract Accepted -
SAN DIEGO, June 1, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA ) announced today that a late-breaking abstract of its lorcaserin Phase 3 BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesity Management) tr...
Celladon Announces Presentation of Clinical Data From First-in-Human MYDICAR(R) Trial for Advanced Heart Failure at American Heart Association Scientific Sessions
Phase 1 Data Demonstrate Safety and Improvement in Heart Failure in a Majority of Patients
NEW ORLEANS, Nov. 9 /PRNewswire/ -- Celladon Corporation announced
today results from the first nine patients treated with MYDICAR(R), a
genetically-targeted enzyme replacement ...
Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions
Results of Mouse Model of Diabetes with Haptoglobin 2-2 Genotype Show
Modification of HDL Structure and Defective Reverse Cholesterol Transport
MONTVALE, N.J., March 31 /PRNewswire-FirstCall/ -- Synvista
Therapeutics, Inc. (Amex: SYI ) announces data from a study of diabetic mice
with the H...
Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
In Phase I Clinical Evaluation Anticoagulant Inhibits Clotting Factor IXa; Matched Antidote Rapidly Reverses Anticoagulant Effect
ORLANDO, Fla., Nov. 6 /PRNewswire/ -- Regado Biosciences today
presented encouraging data from Phase Ia and Phase Ib dose escalation
studies of the Company's...
New Risk Factor for Heart Disease Identified in Very Young Children, According to Study at American Heart Association Scientific Sessions
Cincinnati Children's Researcher Says 'Body Mass Index (BMI) Rebound Age'
Can Predict Heart Disease and Calls for Pediatricians To Begin Measuring Children's BMI As Early as Age 3
ORLANDO, Fla., Nov. 5 /PRNewswire/ -- The results from the newest study
in a continuum of rese...
Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
Study Supports Dose-dependent Activity of Antidote Component
ORLANDO, Fla., Nov. 4 /PRNewswire/ -- Regado Biosciences today
presented data from a randomized, double-blind, placebo-controlled Phase Ic
study of the Company's REG1 Anticoagulation System. REG1 is a two-component
Orexigen Therapeutics to Present Data on Contrave Impact on
Visceral Fat and Insulin Resistance at American Diabetes
Association 67th Scientific Sessions in Chicago June 23
SAN DIEGO, June 21, 2007 /PRNewswire-FirstCall/ -- Orexigen(TM)
Therapeutics, Inc. , a biopharmaceutical company focused on the
treatment of central nervous system disorders with an initial focus
on obesity, today announced that the Company will present data
about its lead obesity product candidat...
Keryx Biopharmaceuticals, Inc. Announces Poster Presentations
Highlighting Mechanism of Action and Clinical Activity of
Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American
Diabetes Association 67th Scientific Sessions in Chicago, Illinois
NEW YORK, June 22, 2007 /PRNewswire-FirstCall/ -- Keryx
Biopharmaceuticals, Inc. today announced that abstracts related to
Sulonex(TM) (sulodexide oral gelcap) have been selected for
publication or presentation during the poster sessions
take place at the upcoming American Diabetes As...
Nasulin Interim Results to Be Presented at American Diabetes
Association Scientific Sessions
EXETER, N.H.--(BUSINESS WIRE)--Apr 10, 2007 - Bentley
Pharmaceuticals, Inc. (NYSE: BNT), a specialty pharmaceutical
company, today announced that its abstract entitled "Interim
Results of a Randomized, Single-Dose, 4-Way Crossover,
Pharmacokinetic Study of Intranasal Insulin Spray (Nasulin(TM)),
Bentley Late Breaking Abstract Accepted for Poster Presentation at
American Diabetes Association Scientific Sessions
EXETER, N.H.--(BUSINESS WIRE)--May 24, 2007 - Bentley
Pharmaceuticals, Inc. (NYSE: BNT), a specialty pharmaceutical
company, today announced that a late breaking abstract sponsored by
the Company has been accepted for a poster presentation at the
American Diabetes Association 67th Scientific Sessio...
Genaera to Present Preclinical Data on Trodusquemine for the
Treatment of Obesity at the American Diabetes Association 67th
PLYMOUTH MEETING, Pa., June 19, 2007 /PRNewswire-FirstCall/ --
Genaera Corporation today announced that it will present a poster
on trodusquemine (MSI-1436), its novel anti-obesity compound,
during the American Diabetes Association (ADA) 67th Scientific
Sessions, June 22 to 25 in Chicago.
MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating
MacroVascular Outcomes Presented at the American Diabetes
Association 67th Scientific Sessions
CHICAGO, June 21, 2007 /PRNewswire/ --
What and When
Data from the PROactive and CHICAGO studies of ACTOS(R)
(pioglitazone HCl) will be presented in poster format at the 67th
of the American Diabetes Association in
-- Hospitalizations for serious adverse eve...
VIVUS Announces Abstract Published at American Diabetes Association
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Jun 25, 2007 - VIVUS, Inc.
(NASDAQ: VVUS), a pharmaceutical company dedicated to the
development and commercialization of novel therapeutic products,
announced that Abstract #2209-PO, Evaluation of Glycemic Parameters
in Obese Diabetic Patients Treated with P...
Society of Gynecologic Oncologists Issues White Paper on HPV Vaccine's Impact on Cervical Cancer Prevention
...s attended by more than 50 thought-leaders and cervical cancer experts from clinical, medical, epidemiology, regulatory and public health backgrounds. sessions
throughout the day and a half meeting explored issues and concerns of public policy, clinical and cost effective issues surrounding the future of cerv...
British Woman Celebrates a Year of Living Cancer-Free
...d cells. Common courses of treatment include chemotherapy, radiation therapy and bone marrow transplantation.
Ms. Scott underwent three to four sessions
of chemotherapy -- she can't remember the exact number and doesn't want to reflect too long on such a painful part of her past -- but the cancer retur...
Clinical and Histopathological Results Using Pollogen's TriPollar(TM) Radio Frequency Technology Published in the June Issue of the Journal of Cosmetic and Laser Therapy
...invasive solution for skin tightening and body
The study involved twelve patients who underwent an average of seven
weekly treatment sessions
on different body areas including the face, neck,
arms, hands and abdomen. One patient consented to a series of TriPollar(TM)
treatments prior to her ...
Scottsdale Facility to Be First in U.S. to Showcase True REST Technology
...group were entirely pain-free, and 56 percent experienced a clear improvement, reported the International Journal of Stress Management.
True REST sessions
are priced on either a single session, monthly, twice a month or weekly rates. Group rates are available upon request. Reservations are being accepted...
Overview of Pixantrone Phase III Clinical Data Presentation at American Society of Clinical Oncology 2009 Annual Meeting Now Available at Clinical Care Options
...mation to healthcare professionals through conference coverage and other educational programs. The ASCO summaries are "quick read" reviews of key oral sessions
and poster presentations, which are handpicked by leading experts in oncology and hematology for the Clinical Care Options website.
About Cell T...
Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009
...d Drug Administration's (FDA's) guidance for evaluating CV risk in type 2 diabetes agents. These findings were presented at the 69th Annual Scientific sessions
of the American Diabetes Association (ADA) in New Orleans.
In the meta-analysis of 12 completed, randomized, controlled clinical trials of 12-52 ...
FYI From Human Genome Sciences: GlaxoSmithKline Study Shows GSK's Novel Diabetes Treatment Syncria(R) (Albiglutide) Improves Glucose Control, Reduces Weight
...erday by GlaxoSmithKline (GSK), regarding new Phase 2 data for Syncria(R) (albiglutide) presented at the American Diabetes Association 69th Scientific sessions
in New Orleans.
(Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO )
Syncria is a biological product generated from the genet...
New Heart Ultrasound Research Reveals Life-Saving Treatment Alternatives and Advancements for Heart Patients
... Breakthrough findings unveiled at the American Society of Echocardiography's Scientific sessions
WASHINGTON, June 8 /PRNewswire/ -- The American Society of Echocardiography (ASE) welcomes the world's leading researchers in cardiovascular ...
Research: Popular Diabetes Medications Associated with Increase in Bone Fractures
... FRANKLIN LAKES, N.J., June 8, /PRNewswire-FirstCall/ -- Research presented at the American Diabetes Association's 69th Scientific sessions
points to increased risk for people with diabetes associated with two widely used drug classes; while another study shed new light on a different clas...
Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control With Weight Loss Over Two Years: DURATION-1 Interim Long-Term Data Presented at ADA 2009
...s of treatment with exenatide once weekly, an investigational therapy for type 2 diabetes. These findings were presented at the 69th Annual Scientific sessions
of the American Diabetes Association (ADA) in New Orleans. A New Drug Application (NDA) for exenatide once weekly was recently submitted to the U.S. F...
Two-Year Data Show Investigational Drug Liraglutide More Effective at Lowering Blood Sugar Than Glimepiride: Oral 162
... NEW ORLEANS, June 7 /PRNewswire-FirstCall/ -- Novo Nordisk (NVO) data presented today at the 69th Annual Scientific sessions
of the American Diabetes Association (ADA) showed that once-daily liraglutide, taken as monotherapy, leads to statistically significant and sustained ...
Study Shows GSK's Novel Diabetes Treatment SYNCRIA(R) (albiglutide) Improves Glucose Control and Reduces Weight
...E PARK, N.C., and NEW ORLEANS, June 7 /PRNewswire-FirstCall/ -- New Phase II data presented today at the American Diabetes Association 69th Scientific sessions
in New Orleans show that the investigational type 2 diabetes treatment Syncria(R) (albiglutide) significantly reduced blood glucose levels and provide...
Studies Show AFRESA(R) Controls Post-Meal Sugar Levels With Less Weight Gain and Hypoglycemia Risk for Diabetes Patients
... Latest data on ultra rapid acting insulin presented at the American Diabetes Association's 69th Scientific sessions
NEW ORLEANS, June 6 /PRNewswire-FirstCall/ -- The findings of two 52-week studies show that the investigational ultra rapid acting insulin A...
New Study Showed Lantus(R) Plus One, Two or Three Shots of Apidra(R) Lowered Patients' Blood Sugar
... - Study Presented at 69th Annual ADA Scientific sessions
Examined Efficacy and Safety of Basal-Prandial Treatment with Lantus(R) and...OADs).The study was presented as a poster during the 69th Annual Scientific sessions
of the American Diabetes Association (ADA).
The study was a multicen...
Boehringer Ingelheim Unveils Diabetes Pipeline
...e 4 (DPP-4) inhibitor and the Company's lead diabetes compound, were presented today at the 69th Annual American Diabetes Association (ADA) Scientific sessions
in New Orleans.
"Type 2 diabetes is a growing public health concern," said J. Martin Carroll, Boehringer Ingelheim USA Corporation presiden...
Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary Endpoints Associated with Cardiovascular Risk
... - Late-Breaking Data from Pivotal BLOOM Trial Presented at the American Diabetes Association's 69th Scientific sessions
Expand on Previously Announced Positive Top-Line Results -
NEW ORLEANS, June 6, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasd...
AFRESA(R) Phase 3 Pulmonary Function Safety Data in Patients with Diabetes Presented at ADA
... Two-year study presented at the American Diabetes Association's 69th Scientific sessions
shows investigational product comparable to standard insulin therapy in pulmonary function tests
NEW ORLEANS, June 6 /PRNewswire-FirstCall/ -- AF...
TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry
...ices announced today at the 30th Annual Scientific sessions
of the Heart Rhythm Society the initial, interim c... part of the Heart Rhythm 2009 Official Scientific sessions
as planned by the HRS Scientific sessions
de Oliveira et al, C...
New MADIT II Clinical Data Analysis Shows Long-Term Survival Benefit for Implantable Defibrillator Therapy
...benefits of ICDs in a primary prevention population. The analysis was presented during a late-breaking session at the Heart Rhythm Society Scientific sessions
The analysis shows a sustainable mortality benefit over time, including:
At eight years, one life is saved for eve...